Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan

BACKGROUND: Vedolizumab (VDZ) was approved by the Japanese Ministry of Health, Labor and Welfare in 2018 for the treatment of patients with moderate-to-severe active ulcerative colitis (UC). The comparative cost-effectiveness of VDZ compared with other biologics is unknown in Japan. This information...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez, Luis, Kuwabara, Hiroyo, Shah, Anshul, Yamabe, Kaoru, Burnett, Heather, Fahrbach, Kyle, Koufopoulou, Maria, Iwakiri, Ryuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081652/
https://www.ncbi.nlm.nih.gov/pubmed/31552601
http://dx.doi.org/10.1007/s40273-019-00841-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081652/
https://www.ncbi.nlm.nih.gov/pubmed/31552601
http://dx.doi.org/10.1007/s40273-019-00841-1

Ejemplares similares